Zentalis Pharmaceuticals Inc.
ZNTLHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase2 readout (azenosertib): Dec 2026. Short interest: 10.4% of float.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.